Disc Medicine (IRON) EPS (Weighted Average and Diluted) (2021 - 2026)
Disc Medicine (IRON) reported EPS (Weighted Average and Diluted) of -$1.65 for Q1 2026, down 61.76% year-over-year from -$4.32 in Q1 2025, and down 1.85% on a QoQ basis from -$1.62 in Q4 2025.
Disc Medicine (IRON) has 6 years of EPS (Weighted Average and Diluted) data on file, last reported at -$1.65 in Q1 2026.
- Quarterly EPS (Weighted Average and Diluted) fell 61.76% year-over-year to -$1.65 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$6.62 (down 68.88% YoY) and the FY2025 annual result came in at -$6.01, down 51.77% from the prior year.
- EPS (Weighted Average and Diluted) retreated to -$1.65 in Q1 2026 per IRON's latest filing, from -$1.62 in the prior quarter.
- Across five years, EPS (Weighted Average and Diluted) topped out at -$0.58 in Q3 2023 and bottomed at -$16.82 in Q3 2022.
- The 5-year median for EPS (Weighted Average and Diluted) is -$1.2 (2023), against an average of -$3.53.
- The widest annual swing landed in 2022, when EPS (Weighted Average and Diluted) tumbled 3811.63%; it then jumped 96.55% in 2023.
- Tracing IRON's EPS (Weighted Average and Diluted) over 5 years: stood at -$7.32 in 2022, then soared by 86.75% to -$0.97 in 2023, then decreased by 1.03% to -$0.98 in 2024, then sank by 65.31% to -$1.62 in 2025, then declined by 1.85% to -$1.65 in 2026.
- Per Business Quant, the three latest IRON EPS (Weighted Average and Diluted) figures stand at -$1.65 (Q1 2026), -$1.62 (Q4 2025), and -$1.77 (Q3 2025).
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EPS (Weighted Avg. Diluted) (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | -4.43 |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | 3,086.42 |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | 0.00 |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | 4.02 |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | 6.75 |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | 1.51 |
| 10 | Disc Medicine | 2.76 Bn | 2.03 Bn | - | -1.65 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -1.65 |
| Dec 31, 2025 | -1.62 |
| Sep 30, 2025 | -1.77 |
| Jun 30, 2025 | -1.58 |
| Mar 31, 2025 | -1.02 |
| Dec 31, 2024 | -0.98 |
| Sep 30, 2024 | -0.89 |
| Jun 30, 2024 | -1.03 |
| Mar 31, 2024 | -1.09 |
| Dec 31, 2023 | -0.97 |
| Sep 30, 2023 | -0.58 |
| Jun 30, 2023 | -0.74 |
| Mar 31, 2023 | -1.20 |
| Dec 31, 2022 | -7.32 |
| Sep 30, 2022 | -16.82 |
| Jun 30, 2022 | -10.14 |
| Mar 31, 2022 | -10.67 |
| Dec 31, 2021 | -39.58 |
| Sep 30, 2021 | -0.43 |
| Jun 30, 2021 | -0.38 |